UK-headquartered contract research organisation (CRO) has appointed Roger Hunter as vice president of strategic partnerships within its business development team.
He brings 25 years of pharma and biotech experience to the company and his most recent industry-side role was as VP of operations for a speciality pharmaceutical company.
Chiltern's VP of global business development Stuart McGuire said: “It gives me great pleasure to welcome Roger Hunter as Chiltern's new VP of strategic partnerships. Roger comes to us with a strong background in both commercial and development functions within pharma and biotech. He has a strong understanding of clinical development and a deep appreciation of the impact that we have on our clients.”
Roger Hunter added: “I look forward to working in close collaboration with our sponsors to develop long standing strategic partnerships with them through the delivery of innovative, quality and flexible solutions that address their key needs.”
No results were found
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...